Wet Age-Related Macular Degeneration Pipeline Drugs Analysis Report (2023 Updates): FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | IVERIC bio (formerly Ophthotech Corporation), Ribomic, Curacle, Bio-Thera Solutions, AngioLab Inc, Al

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Wet Age-Related Macular Degeneration pipeline constitutes 75+ key companies continuously working towards developing 80+ Wet Age-Related Macular Degeneration treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Wet Age-Related Macular Degeneration Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Wet Age-Related Macular Degeneration Market.

The Wet Age-Related Macular Degeneration Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Wet Age-Related Macular Degeneration Pipeline Report: https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Wet Age-Related Macular Degeneration treatment therapies with a considerable amount of success over the years.
• Wet Age-Related Macular Degeneration companies working in the treatment market are Akari Therapeutics, Apellis Pharmaceuticals, Shanghai Biomabs Pharmaceutical, Ocular Therapeutix, Clearside Biomedical, RemeGen, Ribomic, Isarna Therapeutics, Alkahes, Henlius Biotech, REGENXBIO, Luye Pharma, Kodiak Sciences, Gemini Therapeutics, Iveric Bio, Boehringer Ingelheim, Janssen Research and Development, and others, are developing therapies for the Wet Age-Related Macular Degeneration treatment
• Emerging Wet Age-Related Macular Degeneration therapies in the different phases of clinical trials are- Nomacopan, APL-2006, CMAB818, OTX-TKI, CLS-AX, RC 28 E, RBM-007, ISTH0036, ALK4290, HLX04-OShanghai, RGX-314, LY09004, KSI-301, GEM-103, Zimura, BI 836880, AAVCAGsCD59, and others are expected to have a significant impact on the Wet Age-Related Macular Degeneration market in the coming years.
• In August 2022, Opthea Limited has revealed a non-dilutive funding arrangement of up to US$170 million from investment funds collaborating with Launch Therapeutics (Launch Tx). This funding is designated to support and propel the progression of ongoing Phase 3 clinical trials and pre-commercialization initiatives of OPT-302 intended for the treatment of wet age-related macular degeneration (wet AMD).
• In August 2022, Outlook Therapeutics, Inc. has communicated the resubmission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ONS-5010, an investigative ophthalmic treatment that, upon approval, is anticipated to be marketed under the name LYTENAVA™ (bevacizumab-vikg). This application is specifically intended for the management of wet age-related macular degeneration (wet AMD).
• In August 2022, EyePoint Pharmaceuticals, Inc. disclosed the initiation of Phase 2 of the "Durasert® and Vorolanib in Ophthalmology 2" (DAVIO 2) clinical trial for EYP-1901, an investigational prolonged-release anti-vascular endothelial growth factor (anti-VEGF) therapy designed for the treatment of wet age-related macular degeneration (wet AMD), with the administration of the first dose to a patient.
• In August 2022, Alcon and Aerie Pharmaceuticals, Inc. have confirmed their agreement to a definitive merger, where Alcon is set to acquire Aerie Pharmaceuticals, marking a significant development between the two companies.
• In July 2022, REGENXBIO Inc. has announced the successful completion of participant enrollment in Cohort 5 of the Phase II AAVIATE® trial for RGX-314, aimed at treating wet age-related macular degeneration (wet AMD) utilizing in-office suprachoroidal delivery.
• In July 2022, IVERIC bio, Inc. and DelSiTech Ltd have declared an exclusive global licensing pact, granting Iveric Bio the authority to advance and market novel formulations of Zimura® (avacincaptad pegol) employing DelSiTech's sustained release technology based on silica. This agreement is a part of Iveric Bio's strategy to expand Zimura's lifecycle, intending to explore sustained release methods for treating age-related macular degeneration (AMD). These technologies aim to potentially cater to patients undergoing treatment for geographic atrophy (GA) and intermediate AMD.
• In July 2022, Clearside Biomedical, Inc. has revealed the conclusion of administering doses in Cohorts 3 and 4 within the OASIS study, which is its Phase 1/2a clinical trial evaluating CLS-AX (axitinib injectable suspension) among patients diagnosed with neovascular age-related macular degeneration (wet AMD).
• In March 2022, RIBOMIC Inc. has released findings from the investigator-sponsored trial (IST) called TEMPURA, along with updated information from its TOFU and RAMEN studies involving RBM-007, an investigational aptamer targeting anti-fibroblast growth factor-2, for wet age-related macular degeneration (wAMD). Initial indications of efficacy from the TEMPURA study show promising early signs of clinical benefit in individuals with wAMD receiving treatment for the first time. However, upon further examination of Phase 2 TOFU data and insights from the RAMEN study involving previously treated wAMD patients, there was no observable advantage of RBM-007 monotherapy or its combination with Eylea in any of the study's outcome measures. The recent data hints that RBM-007 might exhibit greater effectiveness in individuals experiencing wAMD for the first time compared to those who have received prior treatment.


Wet Age-Related Macular Degeneration Overview
A frequent macular condition known as wet age-related macular degeneration (AMD) is caused by aberrant blood vessels growing into the retina and macula. These cause blood or fluid leaks, which cause the macula to scar and cause central vision loss to occur quickly. This leakage results in a central blind spot (scotoma) in the affected person's visual field and irreversible damage to the light-sensitive retinal cells (photoreceptors) in the macula.

Get a Free Sample PDF Report to know more about Wet Age-Related Macular Degeneration Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/wet-age-related-macular-degeneration-wet-amd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Wet Age-Related Macular Degeneration Drugs Under Different Phases of Clinical Development Include:
• Nomacopan: Akari Therapeutics
• APL-2006: Apellis Pharmaceuticals
• CMAB818: Shanghai Biomabs Pharmaceutical
• OTX-TKI: Ocular Therapeutix
• CLS-AX: Clearside Biomedical
• RC 28 E: RemeGen
• RBM-007: Ribomic
• ISTH0036: Isarna Therapeutics
• ALK4290: Alkahes
• HLX04-OShanghai: Henlius Biotech
• RGX-314: REGENXBIO
• LY09004: Luye Pharma
• KSI-301: Kodiak Sciences
• GEM-103: Gemini Therapeutics
• Zimura: Iveric Bio
• BI 836880: Boehringer Ingelheim
• AAVCAGsCD59: Janssen Research and Development

Wet Age-Related Macular Degeneration Route of Administration
Wet Age-Related Macular Degeneration pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Wet Age-Related Macular Degeneration Molecule Type
Wet Age-Related Macular Degeneration Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Wet Age-Related Macular Degeneration Pipeline Therapeutics Assessment
• Wet Age-Related Macular Degeneration Assessment by Product Type
• Wet Age-Related Macular Degeneration By Stage and Product Type
• Wet Age-Related Macular Degeneration Assessment by Route of Administration
• Wet Age-Related Macular Degeneration By Stage and Route of Administration
• Wet Age-Related Macular Degeneration Assessment by Molecule Type
• Wet Age-Related Macular Degeneration by Stage and Molecule Type
DelveInsight's Wet Age-Related Macular Degeneration Report covers around 80+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Wet Age-Related Macular Degeneration product details are provided in the report. Download the Wet Age-Related Macular Degeneration pipeline report to learn more about the emerging Wet Age-Related Macular Degeneration therapies at:
https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Wet Age-Related Macular Degeneration Therapeutics Market include:
Key companies developing therapies for Wet Age-Related Macular Degeneration are - IVERIC bio (formerly Ophthotech Corporation), Ribomic, Curacle, Bio-Thera Solutions, AngioLab Inc, Alkahest, Tyrogenex, Opthea Limited, Outlook Therapeutics, Kodiak Sciences, Regenxbio, Dobecure, Gemini Therapeutics, Huabo Biopharm, Isarna Therapeutics, Iconic Therapeutics, AiViva BioPharma, Boehringer Ingelheim, RemeGen, PanOptica, Clearside Biomedical, Feramda, AsclepiX Therapeutics, Unity Biotechnology, Kyowa Kirin, Ocular Therapeutix, Janssen Research & Development, EyePoint Pharmaceuticals, and others.

Wet Age-Related Macular Degeneration Pipeline Analysis:
The Wet Age-Related Macular Degeneration pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Wet Age-Related Macular Degeneration with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Wet Age-Related Macular Degeneration Treatment.
• Wet Age-Related Macular Degeneration key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Wet Age-Related Macular Degeneration Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Wet Age-Related Macular Degeneration market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Wet Age-Related Macular Degeneration drugs and therapies-
https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Wet Age-Related Macular Degeneration Pipeline Market Drivers
Rise in ageing population, entry of biosimilars, robust pipeline are some of the important factors that are fueling the Wet Age-Related Macular Degeneration Market.

Wet Age-Related Macular Degeneration Pipeline Market Barriers
However, burden of medical treatment, high cost associated with antiVEGF agents, decrease in quality of life and other factors are creating obstacles in the Wet Age-Related Macular Degeneration Market growth.

Scope of Wet Age-Related Macular Degeneration Pipeline Drug Insight
• Coverage: Global
• Key Wet Age-Related Macular Degeneration Companies: Akari Therapeutics, Apellis Pharmaceuticals, Shanghai Biomabs Pharmaceutical, Ocular Therapeutix, Clearside Biomedical, RemeGen, Ribomic, Isarna Therapeutics, Alkahes, Henlius Biotech, REGENXBIO, Luye Pharma, Kodiak Sciences, Gemini Therapeutics, Iveric Bio, Boehringer Ingelheim, Janssen Research and Development, and others
• Key Wet Age-Related Macular Degeneration Therapies: Nomacopan, APL-2006, CMAB818, OTX-TKI, CLS-AX, RC 28 E, RBM-007, ISTH0036, ALK4290, HLX04-OShanghai, RGX-314, LY09004, KSI-301, GEM-103, Zimura, BI 836880, AAVCAGsCD59, and others
• Wet Age-Related Macular Degeneration Therapeutic Assessment: Wet Age-Related Macular Degeneration current marketed and Wet Age-Related Macular Degeneration emerging therapies
• Wet Age-Related Macular Degeneration Market Dynamics: Wet Age-Related Macular Degeneration market drivers and Wet Age-Related Macular Degeneration market barriers

Request for Sample PDF Report for Wet Age-Related Macular Degeneration Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Wet Age-Related Macular Degeneration Report Introduction
2. Wet Age-Related Macular Degeneration Executive Summary
3. Wet Age-Related Macular Degeneration Overview
4. Wet Age-Related Macular Degeneration- Analytical Perspective In-depth Commercial Assessment
5. Wet Age-Related Macular Degeneration Pipeline Therapeutics
6. Wet Age-Related Macular Degeneration Late Stage Products (Phase II/III)
7. Wet Age-Related Macular Degeneration Mid Stage Products (Phase II)
8. Wet Age-Related Macular Degeneration Early Stage Products (Phase I)
9. Wet Age-Related Macular Degeneration Preclinical Stage Products
10. Wet Age-Related Macular Degeneration Therapeutics Assessment
11. Wet Age-Related Macular Degeneration Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Wet Age-Related Macular Degeneration Key Companies
14. Wet Age-Related Macular Degeneration Key Products
15. Wet Age-Related Macular Degeneration Unmet Needs
16 . Wet Age-Related Macular Degeneration Market Drivers and Barriers
17. Wet Age-Related Macular Degeneration Future Perspectives and Conclusion
18. Wet Age-Related Macular Degeneration Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Wet Age-Related Macular Degeneration Market https://www.delveinsight.com/report-store/wet-age-related-macular-degeneration-wet-amd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Wet Age-Related Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Wet Age-Related Macular Degeneration Epidemiology https://www.delveinsight.com/report-store/wet-age-related-macular-degeneration-wet-amd-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Wet Age-Related Macular Degeneration Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:
Cancer Immunotherapy Market
https://www.delveinsight.com/report-store/cancer-immunotherapy-market
Cancer Immunotherapy Market By Type (Monoclonal Antibodies, Immunomodulators, Cancer Vaccines, Checkpoint Inhibitors, And Others), By Indication (Lung Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, And Others), By End-User (Hospitals And Clinics, Specialty Centers, And Others), and by geography is expected to rise at a significant CAGR forecast till 2027 owing to the accelerating prevalence of cancers and surging healthcare expenditure across the globe

Companion Diagnostics Market
https://www.delveinsight.com/report-store/companion-diagnostics-market
Companion Diagnostics Market By Type (Product [Assays, Kits & Reagents And Instruments], and Services), Technology (Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), and Others), Indication (Lung Cancer, Breast Cancer, Colorectal Cancer, and Others), End-User (Hospitals, Diagnostic Labs, and Others), and Geography is expected to grow at a noteworthy CAGR till 2028 owing to the increase in the cancer burden across the globe and the growing focus on personalized medicines.

Telemedicine Service Market
https://www.delveinsight.com/report-store/telemedicine-service-market
Telemedicine Service Market By Service Type (Tele Consulting And Tele Monitoring), By Application (Telepathology, Telecardiology, Teleradiology, Teledermatology, Telepsychiatry, Other Services), By End-User (Healthcare Facilities And Homecare), by geography, is projected to grow at a significant CAGR forecast till 2028 owing to the sudden outbreak of covid-19 pandemic and shifting focus for reducing the burden of healthcare cost.

DNA Sequencing Market
https://www.delveinsight.com/report-store/dna-sequencing-market
DNA Sequencing Market By Products & Services (Instruments, Consumbales, And Services), By Technology (Sanger Sequencing, Next-Generation Sequencing, And Long-Read Sequencing), By Application (Disease Diagnosis, Precision Medicine, And Research), By End User (Hospitals & Clinics, Diagnostic Laboratories, Pharmaceutical Companies, And Academic Institutes), and by geography is estimated to grow at an appreciable CAGR forecast till 2028 owing to rising prevalence of genetic disorders and growing popularity of precision medicine.

Next Generation Sequencing Market
https://www.delveinsight.com/report-store/next-generation-sequencing-market
Next-Generation Sequencing Market By Product Type (Instruments, Reagents & Consumables And Services), By Sequencing Type (Whole-Genome Sequencing, Whole-Exome Sequencing, Rna Sequencing, Targeted Sequencing, De-Novo Sequencing, Others), By Application (Diagnostic, Drug Discovery, Agriculture & Animal Research, Others), By End-User (Pharmaceutical & Biotechnology Companies, Hospitals & Clinics, Academic & Research Institute), by geography, is expected to grow at a significant CAGR forecast till 2028 owing to the rising application of next-generation sequencing (NGS) technology in clinical diagnosis and advancement in NGS platforms.

Active Pharmaceutical Ingredient Market
https://www.delveinsight.com/report-store/active-pharmaceutical-ingredient-api-market
Active Pharmaceutical Ingredient (API) Market By Type (Innovative And Generic), By Manufacturer Type (Captive And Merchant), By Synthesis Type (Synthetic And Biotech), By Application (Oncology, Cardiology, Pulmonology, Neurology, Orthopedic, Opthalmology, And Others), by geography is estimated to register growth at remarkable CAGR forecast till 2027 owing to rising prevalence of various diseases such as diabetes and growing focus on drug development

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+91-9650213330
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.